ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 581,12
-0,68%
Dow Jones
40 211,72
0,53%
DAX
18 526,37
-0,40%
Brent Oil
83,585
-0,90%
Bitcoin
63 483,98
-2,10%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
25/05/202215h36Business WireTeva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
25/05/202214h01Edgar (US Regulatory)Specialized Disclosure Report (sd)NYSE:TEVATeva Pharmaceutical Industries Ltd
23/05/202214h00Business WireTeva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
19/05/202213h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
18/05/202200h26Business WirePremière licence accordée au Royaume-Uni pour le biosimilaire ophtalmologique de Teva, Ongavia (ranibizumab)▼NYSE:TEVATeva Pharmaceutical Industries Ltd
17/05/202221h02Business WireGroßbritannien erteilt als erstes Land eine Zulassung für das ophthalmologische Biosimilar Ongavia (Ranibizumab) von Teva▼NYSE:TEVATeva Pharmaceutical Industries Ltd
17/05/202215h10Business WireUnited Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼NYSE:TEVATeva Pharmaceutical Industries Ltd
17/05/202214h00Business WireTeva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
17/05/202213h45Business WireTeva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment ChallengesNYSE:TEVATeva Pharmaceutical Industries Ltd
12/05/202214h00Business WireTeva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
10/05/202214h00Business WireTeva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance StructureNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/202222h08Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/202213h00Business WireTeva Reports First Quarter 2022 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
02/05/202214h00Business WireTeva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent DisputeNYSE:TEVATeva Pharmaceutical Industries Ltd
20/04/202214h54TipRanksTeva Hits FDA Hurdle, Slips 4.5% Pre-MarketNYSE:TEVATeva Pharmaceutical Industries Ltd
20/04/202200h10Dow Jones NewsTeva Pharmaceutical Industries Shares Retreat After FDA Rejection LetterNYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/202223h15Business WireTeva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRMNYSE:TEVATeva Pharmaceutical Industries Ltd
05/04/202213h34PR Newswire (Canada)Teva Canada Charts a New Prescription for CareNYSE:TEVATeva Pharmaceutical Industries Ltd
04/04/202222h05Business WireTeva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022NYSE:TEVATeva Pharmaceutical Industries Ltd
01/04/202214h00Business WireTeva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
31/03/202217h58TipRanksTeva Gains 6.4% on Another Opioid Case SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
30/03/202215h55Dow Jones NewsTeva in Agreement With Florida to Settle Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
30/03/202215h09Business WireTeva Reaches Agreement With Florida to Settle the State’s Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
22/03/202212h47TipRanksTeva Settles Opioid Case with Rhode Island, Aims National SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
21/03/202220h45Dow Jones NewsTeva Pharmaceuticals Agrees to Pay Rhode Island $21 Million, Provide Opioid Treatment OptionsNYSE:TEVATeva Pharmaceutical Industries Ltd
21/03/202219h55Business WireTeva Reaches Agreement With Rhode Island to Settle Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
15/03/202221h03Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202214h00Business WireTeva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
02/03/202213h33PR Newswire (Canada)Teva Canada se réjouit du remboursement d'AJOVY(MD) (frémanezumab)par les régimes publics d'assurance médicaments de l'Alberta, de la Saskatchewan, du Québec ainsi que par le ACC et le Programme SSNA aux patients prescrit AJOVY(MD)NYSE:TEVATeva Pharmaceutical Industries Ltd
02/03/202213h33PR Newswire (Canada)Teva Canada Welcomes Public Drug Plan Reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY® (fremanezumab) for the Preventive Treatment of Migraine in AdultsNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

BIT
P1WND2
NLBNPIT1WND2 20240920 800
LSE
NBPS
Nb Priv. Zdp 24
LSE
0JQI
Kennedy-wilson
LSE
0OG6
Seche Environnement
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés